ClinicalTrials.Veeva

Menu
A

Alliance Clinical Research of Tampa | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SCD-044
Vedolizumab
LY3041658
PF-06480605
Ustekinumab
PF-06700841
GLPG3667
Mirikizumab
Tofacitinib
Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 19 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting
Crohn's Disease
Drug: Mirikizumab

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Biological: Matching placebo

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab togeth...

Enrolling
Crohn's Disease
Drug: Vedolizumab
Drug: Adalimumab

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moder...

Enrolling
Ulcerative Colitis
Drug: Tofacitinib
Drug: Vedolizumab

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Lutikizumab
Drug: Placebo

ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with...

Enrolling
Ulcerative Colitis
Biological: ALTB-268

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Enrolling
Dermatitis Atopic
Drug: Oral corticosteroids
Drug: Amlitelimab

The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get...

Active, not recruiting
Ulcerative Colitis Flare
Ulcerative
Drug: PL8177 Placebo
Drug: PL8177

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Active, not recruiting
Moderate to Severe Plaque Psoriasis
Drug: Placebo
Drug: SCD-044_Dose 3

Trial sponsors

AbbVie logo
Lilly logo
Pfizer logo
Sun Pharma logo
Takeda logo
A
A
Celldex Therapeutics logo
G
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems